Further understanding of CLR signaling pathways and immune outcomes in each DC subset together with the tumor glyco-code is crucial to deeply decipher the complexity of interactions between cancer cells and immune cells within the tumor microenvironment, and exploit the glycan/CLR axis in immunotherapy. The gene discussed is DCLK3; the disease is cancer.